Additional file 1: of Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nabÂŽ-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

Raw data that supports the conclusion. (XLS 763 kb

MOESM1 of A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Additional file 1. Questionnaire for survey of the clinical features and management of bone metastatic disease in China

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis

<div><p>Background</p><p>The clinical outcomes of patients with NSCLC who progressed after first-line treatments remain poor. The purpose of this study was to assess the advantage of antiangiogenic therapy plus standard treatment versus standard treatment alone for this population of patients.</p><p>Methods</p><p>We conducted a rigorous search using electronic databases for eligible studies reporting antiangiogenic therapy combined with standard second-line chemotherapy versus standard second-line treatment for patient who progressed after front-line treatment. Pooled risk ratio and 95% confidence intervals were calculated using proper statistical method. Predefined subgroup analyses were conducted to identify the potential proper patients.</p><p>Results</p><p>Thirteen phase II/III RCTs which involved a total of 8358 participants were included. Overall, there was significant improvement in OS (HR 0.94, 95%CI: 0.89-0.99, p=0.03), PFS (HR 0.80, 95%CI: 0.76-0.84, p<0.00001), ORR (RR 1.75, 95%CI: 1.55-1.98, p<0.00001) and DCR (RR 1.23, 95%CI: 1.18-1.28, p<0.00001) in the group with antiangiogenic therapy plus standard treatment versus the group with standard treatment alone. Subgroup analysis showed that OS benefit was presented only in patients treated with docetaxel plus antiangiogenic agents (HR 0.92, 95%CI: 0.86-0.99, p=0.02) and patients with non-squamous NSCLC (HR for OS 0.92, 95%CI: 0.86-0.99, p=0.02).</p><p>Conclusions</p><p>This study revealed that the addition of antiangiogenic agents to the standard treatments could provide clinical benefit to NSCLC patients who failed their first-line therapy. Furthermore, proper selection of the combined standard cytotoxic agent, as well as the patient population by tumor histology, is warranted for future studies and clinical application of antiangiogenic therapy.</p></div

Additional file 2: Figure S2. of Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)

Representative image of immunostaining of LDLR expression in healthy lung tissue (Original magnification 200×). (TIFF 6774 kb

Forest plot and pooled RR & 95%CI for ORR (left) and DCR (right): Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.

<p>Forest plot and pooled RR & 95%CI for ORR (left) and DCR (right): Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.</p

Forest plot and pooled HR & 95%CI for PFS: Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.

<p>Forest plot and pooled HR & 95%CI for PFS: Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.</p

Forest plot and pooled HR & 95%CI for OS: Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.

<p>Forest plot and pooled HR & 95%CI for OS: Antiangiogenic agents plus single agent chemotherapy versus standard second-line chemotherapy.</p

Summary of the subgroup results: Pooled HR & 95%CI for OS.

<p>* AT for antiangiogenic-TKI;</p><p>^& AA refers to antiangiogenic antibody;</p><p>^¶ Double TKI means antiangiogenic-TKI plus EGFR-TKI.</p><p>Summary of the subgroup results: Pooled HR & 95%CI for OS.</p

Qualitative analysis of publication bias: Funnel plot of included studies for all outcome.

<p>(A) OS, (B) ORR, (C) PFS and (D) DCR.</p

Summary of the subgroup results: Pooled HR & 95%CI for PFS and the corresponding details.

<p>* AT for antiangiogenic-TKI;</p><p>^& AA refers to antiangiogenic antibody.</p><p>^¶ Double TKI means antiangiogenic-TKI plus EGFR-TKI.</p><p>Summary of the subgroup results: Pooled HR & 95%CI for PFS and the corresponding details.</p